Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions.
Julia DietzJohannes VermehrenKatrin MatschenzPeter BuggischHartwig KlinkerJulian Schulze Zur WieschHolger HinrichsenKai-Henrik PeifferChristiana GrafThomas DischerJanina TrauthJörn Markus SchattenbergFelix PiechaStefan MaussClaus NiederauTobias MuellerChristoph Neumann-HaefelinChristoph P BergStefan ZeuzemChristoph Sarrazinnull nullPublished in: Liver international : official journal of the International Association for the Study of the Liver (2020)
EBR/GZR treatment with or without RBV for 12 or 16 weeks according to a baseline RAS analysis was highly effective with ≥97% SVR in patients with genotype 1a. EBR/GZR without RBV should be avoided in patients with RASs. High SVR rates were also achieved using other 8 or 12 weeks DAA regimens.